Neoadjuvant Hormonal Therapy Before Radical Prostatectomy: Favorable Pathological and PSA Outcomes Do Not Guarantee Favorable Oncological Outcomes
The Prostate · 2026-12 · 86 (16) · 1645-1652
DOI: 10.1002/pros.70250 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Prostate, online erschienen am 19.09.2026. Verfasst von Junliang Zhao und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen Univers…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Prostatectomy, Neoadjuvant Therapy, Prostate-Specific Antigen. Die Arbeit nennt 31 Literaturangaben. Gefördert von: National Natural Science Foundation of China., Basic and Applied Basic Research Foundation of Guangdong Province., National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
To evaluate the impact of neoadjuvant hormonal therapy (Neo‐HT) on postoperative pathological and prostate‐specific antigen (PSA) outcomes after radical prostatectomy (RP) and oncological outcomes in patients with favorable postoperative outcomes (pT0‐2N0, negative surgical margin and undetectable PSA).
Methods
A total of 1099 prostate cancer (PCa) patients who underwent RP were divided into the direct RP group or the Neo‐RP group (Neo‐HT before RP). We compared the proportions achieving favorable postoperative outcomes. Oncological endpoints included biochemical progression‐free survival (bPFS), local recurrence‐free survival (LRFS), and metastasis‐free survival (MFS). Predictors of biochemical recurrence (BCR) were identified using multivariable Cox regression. Propensity score matching (PSM) was applied to balance baseline characteristics.
Results
Neo‐HT increased the proportions achieving favorable postoperative outcomes among both low‐to‐intermediate and high‐risk patients (42.02% vs. 23.63%, p < 0.001). Among 362 patients with favorable postoperative outcomes, unadjusted 3‐year bPFS was worse in the Neo‐RP group (81.5% vs. 93.6%, p = 0.008), with similar patterns for LRFS and MFS. Baseline PSA > 20 ng/ml, Gleason score 8–10, and cT2c‐4 were independent predictors of BCR, and no statistically significant differences in bPFS, LRFS, or MFS were observed in the PSM cohort.
Conclusions
Neo‐HT enables more PCa patients to achieve favorable postoperative outcomes. Among patients with favorable postoperative outcomes, those with high‐risk baseline features are more likely to experience BCR irrespective of Neo‐HT. The apparent improvements in postoperative pathological and PSA outcomes after Neo‐HT may obscure recurrence risk, underscoring the need to incorporate baseline characteristics into postoperative risk stratification and management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
- Department of Pathology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
ORCID-Profile: Junliang Zhao, Yuanwei Li, Xinyang Cai, Yijun Zhang, Zhenyu Yang, Yonghong Li
Förderung
- National Natural Science Foundation of China.
- Basic and Applied Basic Research Foundation of Guangdong Province.
- National Natural Science Foundation of China
Zitieren
APA
Zhao, J., Li, Y., Cai, X., Zhao, D., Wang, J., Long, X., Zhang, Y., Cao, Y., Chen, D., Zhou, F., Yang, Z., & Li, Y. (2026). Neoadjuvant Hormonal Therapy Before Radical Prostatectomy: Favorable Pathological and PSA Outcomes Do Not Guarantee Favorable Oncological Outcomes. The Prostate, 86(16), 1645-1652. https://doi.org/10.1002/pros.70250
Vancouver
Zhao J, Li Y, Cai X, Zhao D, Wang J, Long X, et al. Neoadjuvant Hormonal Therapy Before Radical Prostatectomy: Favorable Pathological and PSA Outcomes Do Not Guarantee Favorable Oncological Outcomes. The Prostate. 2026;86(16):1645-1652. doi:10.1002/pros.70250
BibTeX
@article{Zhao2026,
author = {Zhao, Junliang and Li, Yuanwei and Cai, Xinyang and Zhao, Diwei and Wang, Jun and Long, Xingbo and Zhang, Yijun and Cao, Yun and Chen, Dong and Zhou, Fangjian and Yang, Zhenyu and Li, Yonghong},
title = {Neoadjuvant Hormonal Therapy Before Radical Prostatectomy: Favorable Pathological and PSA Outcomes Do Not Guarantee Favorable Oncological Outcomes},
journal = {The Prostate},
year = {2026},
volume = {86},
number = {16},
pages = {1645--1652},
doi = {10.1002/pros.70250}
}
EUVIMED